Print

Management of Bavarian Nordic

Bavarian Nordic is managed under a two-tier structure composed of the Board of Directors and the Corporate Management. The Board is responsible for the overall strategic management and the financial and managerial supervision of Bavarian Nordic A/S as well as for regular evaluation of the work of the Corporate Management. In addition, the Board supervises the Company in a general sense and ensures that it is managed in an adequate manner and in accordance with applicable law and the Company’s articles of association.

Executive Management

Paul Chaplin

Paul Chaplin

President & CEO

Mr. Chaplin joined Bavarian Nordic in 1999. He was appointed executive vice president in 2004 and President & CEO in 2014. Prior to joining the Company, Mr. Chaplin worked for several years both in the UK and Australia developing  vaccines against infectious diseases. Mr. Chaplin holds a Ph.D. in Immunology from Bristol University, and he is the general manager of Bavarian Nordic GmbH. He is a British national, born in 1967.

Ole Larsen

Ole Larsen

Executive Vice President, Chief Financial Officer

Mr. Larsen joined Bavarian Nordic in 2008 from Nordisk Film where he was CFO. Mr. Larsen holds an M.Sc. in economics and business administration from Copenhagen Business School, and he is a Danish national, born in 1965.

Henrik Birk

Henrik Birk

Executive Vice President, Chief Operating Officer

Mr. Birk joined Bavarian Nordic in 2008 from Coloplast where he held various management positions focusing on supply chain and production. Since joining Bavarian Nordic, he has served in positions of increasing responsibility, most recently as Senior Vice President, Strategy, People and Organization. Mr. Birk holds a Masters of Business Administration from Henley Business School, and he is a Danish national, born in 1974.

Board of Directors

Gerard van Odijk, M.D.

Gerard van Odijk, M.D.

Independent member of the board since 2008 and chairman since 2014. Current term expires in 2018. Chairman of the Nomination and Compensation Committee since 2015.

Dr. van Odijk is a Dutch national, born in 1957.

Positions: Independent advisor for the pharmaceutical industry and former president and chief executive officer of Teva Pharmaceuticals Europe B.V. Chairman of the board of HTL-Strefa S.A. and member of the board of UDG Healthcare plc. 

Special competences: Medical qualifications and extensive executive background within publicly traded companies in the international pharmaceutical industry.

Anders Gersel Pedersen, M.D., Ph.D.

Anders Gersel Pedersen, M.D., Ph.D.

Independent member of the board since 2010 and deputy chairman since 2014. Current term expires in 2018. Member of the Finance, Risk and Audit Committee since 2015.

Dr. Pedersen is a Danish national, born in 1951.

Positions: Executive vice president of research and development at H. Lundbeck A/S. Deputy chairman of the board of Genmab A/S and member of the board of ALK-Abelló A/S. 

Special competences: Scientific qualifications, particularly in oncology, and extensive board and management experience from publicly traded, international pharmaceutical and biotech industries.

Claus Bræstrup, Dr. Med.

Claus Bræstrup, Dr. Med.

Independent member of the board since 2008. Current term expires in 2017. Member of the Nomination and Compensation Committee since 2015.

Dr. Braestrup is a Danish national, born in 1945.

Positions: Chairman of the Board of Directors of Saniona AB and Saniona A/S; and a member of the Board of Directors of Evolva Holding SA, Ataxion, Inc. and Evotec AG. Member of the executive board of Kastan ApS.

Special competences: Scientific qualifications and extensive executive experience from publicly traded, international pharmaceutical companies.

Erik G. Hansen, M.Sc.

Erik G. Hansen, M.Sc.

Independent member of the board since 2010. Current term expires in 2018. Chairman of the Finance, Risk and Audit Committee since 2015.

Mr. Hansen is a Danish national, born in 1952.

Positions: CEO of Rigas Invest ApS. Chairman of the Board of Directors of Polaris Management A/S, TTiT A/S, TTiT Ejendomme A/S, Astrup Landbrug A/S and Sirius Holding. Member of the Board of Directors of OKONO A/S (Deputy Chairman), Bagger-Sørensen & Co. A/S (Deputy Chairman) and its six subsidiaries (as Deputy Chairman in two of the subsidiaries and as a board member in four of the subsidiaries, respectively), Bagger-Sørensen Fonden, Lesanco ApS, Ecco Sko A/S, Farumgade 2B Holding ApS, Wide Invest ApS, Nørrebro 2020 Holding ApS, Nørrebro 2020 ApS and Lauritzen Fonden. In addition, Mr Hansen is a member of the Executive Board of Rigas Invest ApS, BFB ApS, Sirius Holding, Tresor ApS, Tresor Asset Advisers ApS, Polaris Invest II ApS and Hansen Advisers ApS. 

Special competences: Training and experience in and thorough understanding of managing finance operations and experience with publicly traded companies.

Peter Kürstein, MBA

Peter Kürstein, MBA

Independent member of the board since 2012. Current term expires in 2018. Member of the Nomination and Compensation Committee since 2015.

Mr. Kürstein is a Danish national, born in 1956.

Chairman of the Board of Directors of Radiometer Medical ApS, Deputy Chairman of the Board of Directors of FOSS A/S and member of the Board of Directors in N. FOSS & Co. A/S, the commercial foundation Gl. Strand (in Danish: Den Erhvervsdrivende Fond Gl. Strand), Experimentarium, One Life and Dansk BørneAstma Center. Furthermore, he is Chairman of the Danish-American Business Forum and the Business Forum for Better Regulation; and an executive officer of ApS Mijamax.

Special competences: Extensive board and management experience from publicly traded, international healthcare companies.

Frank Verwiel, M.D.

Frank Verwiel, M.D.

Independent member of the board since 2016. Current term expires in 2018. Member of the Finance, Risk and Audit Committee since 2016.

Dr. Verwiel is a Dutch national, born in 1962.

Positions: Former President and CEO of Aptalis Pharma, Inc. Member of the Board of Directors of Achillion Pharmaceuticals, Inc., AveXis, Inc. and ObsEva SA.

Special competences: Extensive strategic, operational and international experience within the pharmaceutical industry.

Elizabeth McKee Anderson, MBA

Elizabeth McKee Anderson, MBA

Independent member of the board since 2017. Current term expires in 2018.

Ms. Anderson is an American national, born in 1957.

Positions: Former worldwide vice president Global Strategic Marketing and Market Access, Infectious Diseases and Vaccines for Johnson&Johnson. Member of the board of REVOLUTION Medicines, Inc. and a member of the advisory board of NAXION, Inc. Furthermore, she is a member of the board of trustees of The Haverford School, the Bryn Mawr Hospital Foundation and The Wistar Institute. Principal of PureSight Advisory, LLC.

Special competences: Extensive strategic, operational and international experience within the pharmaceutical industry.